Dr. Wakelee on Immunotherapy Versus Targeted Agents in NSCLC
July 20th 2016Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.
Read More
Dr. Heather Wakelee on What to Do When Resistance to EGFR TKIs Emerges
March 24th 2016Heather Wakelee, MD associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses treating EGFR-mutant patients with lung cancer who are resistant to EGFR tyrosine kinase inhibitors (TKIs).
Read More